Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma

NCT00343564 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT00343564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma
Lead sponsor
Cytokinetics
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2006
Completion date
July 31, 2010
Enrollment
68 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's disease, non-hodgkin's lymphoma